- ►uab.edu [PDF] WM Lee - The New England journal of medicine, 2003 - nejm.highwire.org In the past five years, two drugs have been withdrawn from the market by the
Food and Drug Administration (FDA) for causing severe liver injury, a potential
danger that had not been fully recognized in the course of the preapproval ... Cited by 665 - Related articles - BL Direct - All 22 versions
AA Parulkar, ML Pendergrass, R Granda- … - Ann Intern Med, 2001 - Am Coll Physicians The thiazolidinediones are a new class of compounds for treat- ment of type 2
diabetes. Troglitazone became available in the United States in 1997 but was
withdrawn from the market in March 2000 because it caused severe ... Cited by 417 - Related articles - All 4 versions
SH Caldwell, EE Hespenheide, JA Redick, JC … - The American journal of gastroenterology, 2001 - nature.com Troglitazone is a thiazolidinedione and peroxisome proliferator–activated
receptor gamma (PPAR ) ligand used to treat diabetes mellitus type II. Because
hyperinsulinemia may be a factor in nonalcoholic steatohepatitis (NASH), we ... Cited by 336 - Related articles - BL Direct - All 7 versions
- ►annals.org [PDF] E Arioglu, J Duncan-Morin, N Sebring, KI … - Annals of internal medicine, 2000 - Am Coll Physicians Elif Arioglu, MD; Jennifer Duncan-Morin, RN; Nancy Sebring, RD; Kristina I.
Rother, MD; Nicole Gottlieb, BA; Jay Lieberman, BS; David Herion, MD; David E.
Kleiner, MD, PhD; James Reynolds, MD; Ahalya Premkumar, MD; Anne E. Sumner, ... Cited by 250 - Related articles - BL Direct - All 5 versions
- ►ccf.org [PDF] AJ McCullough - Journal of clinical gastroenterology, 2002 - journals.lww.com Abstract Nonalcoholic fatty liver disease is now recognized as the most common
liver disease in the United States, with a prevalence of approximately 5% in the
general population and up to 25% to 75% in patients with obesity and type ... Cited by 218 - Related articles - BL Direct - All 10 versions
- ►endojournals.org S Matthaei, M Stumvoll, M Kellerer, HU Haring - Endocrine Reviews, 2000 - Endocrine Soc Diabetes mellitus type 2 is a world-wide growing health problem affecting more
than 150 million people at the beginning of the new millennium. It is believed
that this number will double in the next 25 yr. The pathophysiological ... Cited by 205 - Related articles - BL Direct - All 5 versions
- ►dr-agha.com [PDF] K Schoonjans, J Auwerx - The Lancet, 2000 - Elsevier Upon binding to small lipophilic natural ligands, or synthetic molecules such as
the glitazones and certain non-steroidal antiinflammatory drugs, PPARγ
undergoes a conformational change. This stabilises its interaction with the ... Cited by 184 - Related articles - BL Direct - All 7 versions
JH Lewis - Medical Clinics of North America, 2000 - Elsevier A temporal relationship usually is evident with an implicated drug, with most
cases of acute DILD occurring within 1 week to 3 months of exposure. A positive
response to discontinuing the agent (dechallenge) enhances the suspicion, ... Cited by 158 - Related articles - BL Direct - All 20 versions
